Los incentivos en favor de los medicamentos huérfanos

Since 2016, the European Union is considering whether it is necessary or not to review the incentives that EU pharmaceutical legislation contemplates in connection with the research and development of orphan drugs. This article explains which are the current incentives, and which are the main ideas that are currently on the table in connection with such review. The author concludes recommending prudence in the review of a system which has proven to be efficient as regards the achievement of the objectives for which it was designed.